Why is Brawn Biotech falling/rising?

As of 11-Sep, Brawn Biotech Ltd's stock price is currently at 19.81, reflecting a slight increase of 0.01 or 0.05%. The stock has shown a positive performance recently, gaining 4.21% over the last two days and outperforming its sector by 0.34%. However, the stock has experienced a significant decline of 9.95% over the past week and a year-to-date drop of 7.04%. Despite a modest annual return of 2.80%, the company faces challenges, including weak long-term fundamental strength indicated by an average Return on Equity (ROE) of 0% and declining net sales and operating profit over the last five years. Additionally, the stock's liquidity appears adequate, but there has been a notable decrease in investor participation, with delivery volume falling by 16.94% against the five-day average.
In the broader market context, while Brawn Biotech's stock has underperformed the benchmark Sensex over the past week and year-to-date, it has shown some resilience in the one-month period, outperforming the benchmark by a small margin with a return of 13.20% compared to the Sensex's 1.17%. This suggests that while the stock is currently facing headwinds, it has the potential for recovery in the short term. However, the overall negative sentiment surrounding its long-term growth prospects and financial health may continue to weigh on its performance relative to the broader market.